Blog: PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01 Regulation FD Disclosure.

On January 25, 2023, Pulmatrix, Inc. (the “Company”) issued a press release,
attached hereto as Exhibit 99.1, announcing that it will host a virtual key
opinion leader (KOL) event, “PUR3100 for the Treatment of Acute Migraine:
Unlocking Potential of DHE Treatment”.

In accordance with General Instruction B.2 of Form 8-K, the information in this
Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933, as amended,
except as shall be expressly set forth by reference in such a filing.
Furthermore, the furnishing of information under Item 7.01 of this Current
Report on Form 8-K is not intended to constitute a determination by the Company
that the information contained herein, including the exhibits hereto, is
material or that the dissemination of such information is required by Regulation
FD.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit Number   Description

99.1               Press Release, dated January 25, 2023 (furnished herewith
                 pursuant to Item 7.01)
104              Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s